Cargando…

Botulinum toxin-A for the treatment of overactive bladder: UK contributions

BACKGROUND: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactive bladder (OAB) and recognised in many incontinence guidelines and pathways. For those with neurogenic detrusor overactivity secondary to spinal cord injury or multiple sclerosis, the toxin is cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seth, JH, Dowson, C, Khan, MS, Panicker, JN, Fowler, CJ, Dasgupta, P, Sahai, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467228/ https://www.ncbi.nlm.nih.gov/pubmed/26097709 http://dx.doi.org/10.1177/2051415812473096

Ejemplares similares

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)

Emerging treatments for overactive bladder: clinical potential of botulinum toxins
por: Tincello, Douglas G, et al.
Publicado: (2014)

Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder
por: Barba, Marta, et al.
Publicado: (2022)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
por: Wada, Naoki, et al.
Publicado: (2022)

Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment
por: Mahajan, Rajiv, et al.
Publicado: (2011)

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A
por: Wang, Chung-Cheng, et al.
Publicado: (2020)

Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children
por: Tan, Denise Jia Yun, et al.
Publicado: (2022)

Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
por: Cohen, Brian L., et al.
Publicado: (2009)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
por: Mohanty, N. K., et al.
Publicado: (2008)

Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder
por: Abdelwahab, Osama, et al.
Publicado: (2015)

Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?
por: Kim, Shannon HK, et al.
Publicado: (2016)

Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms
por: Seth, Jai H., et al.
Publicado: (2018)

A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder
por: Al-Azzawi, Issam S., et al.
Publicado: (2020)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

RE: Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder
por: Abdelwahab, Osama, et al.
Publicado: (2016)

Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study
por: Nageib, Mohammed, et al.
Publicado: (2019)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?
por: Zargham, Mahtab, et al.
Publicado: (2017)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson’s Disease or Post-Stroke
por: Hu, Ju-Chuan, et al.
Publicado: (2023)

Toxin yet not toxic: Botulinum toxin in dentistry
por: Archana, M.S.
Publicado: (2016)

Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?
por: Hegele, Axel, et al.
Publicado: (2014)

A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages
por: Gu, Hui-Yun, et al.
Publicado: (2017)

Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder
por: Gong, Qin-Qin, et al.
Publicado: (2020)

Perioperative Techniques for the Use of Botulinum Toxin in Overactive Bladder: Results of a Multinational Online Survey of Urogynecologists in Germany, Austria, and Switzerland (†)
por: Lange, Sören, et al.
Publicado: (2023)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

Hengli(®) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
por: Liao, Limin, et al.
Publicado: (2022)

Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients
por: Reekmans, Mathias, et al.
Publicado: (2021)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome
por: Liu, Hsin-Tzu, et al.
Publicado: (2015)

Use of botulinum toxin for voiding dysfunction
por: Eldred-Evans, David, et al.
Publicado: (2017)

Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders
por: Hung, Fan-Ching, et al.
Publicado: (2022)

Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial
por: Szczypior, Michał, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i6e6v2782n2q6jp6pkicdtun8d